---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-25T13:56:41.625839'
end_time: '2026-09-25T14:28:50.172990'
duration_seconds: 1928.55
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Dilated Cardiomyopathy 2B
  mondo_id: MONDO:0013848
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
reference_validation:
  total_references: 12
  verified: 12
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 12
  on_topic: 7
  validator_version: 0.3.0rc1
term_validation:
  total_terms: 26
  verified: 23
  not_found: 0
  obsolete: 1
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 5
  labels_matching: 1
  labels_mismatched: 2
  mislabelled_terms:
  - term_id: HP:0001644
    reported_labels:
    - clinical/imaging sign
    ontology_label: Dilated cardiomyopathy
  - term_id: HP:0001635
    reported_labels:
    - symptoms
    ontology_label: Congestive heart failure
  labels_variant: 2
  obsolete_terms:
  - term_id: GO:0034968
    ontology_label: obsolete histone lysine methylation
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Dilated_Cardiomyopathy_2B-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Dilated_Cardiomyopathy_2B-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Dilated Cardiomyopathy 2B
- **MONDO ID:** MONDO:0013848 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Dilated Cardiomyopathy 2B** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Dilated Cardiomyopathy 2B (CMD2B / GATAD1-related DCM)

**Disease knowledge-base research report**
**MONDO:0013848 · OMIM 614672 · Gene: GATAD1 (7q21.2)**
Date: 2026-09-25

> **Evidence-base caveat.** CMD2B is an ultra-rare Mendelian cardiomyopathy. The
> human clinical description rests essentially on **a single consanguineous
> kindred** (Theis et al. 2011, PMID 21965549). Almost all mechanistic detail
> comes from **in vitro biochemistry** (PMID 38605029, 26841866) and **model
> organisms** (zebrafish PMID 28955713; mouse PMID 39641830, 39626862). Where a
> statement is generic to dilated cardiomyopathy (DCM) as a class rather than
> specific to CMD2B, this is flagged. Source type is labeled throughout as
> [human clinical], [in vitro], [model organism], or [computational/inferred].

---

## 1. Disease Information

**Overview.** Dilated Cardiomyopathy 2B (CMD2B) is a rare **autosomal recessive**
form of familial dilated cardiomyopathy caused by biallelic mutation of
**GATAD1** (GATA zinc-finger domain-containing protein 1). Like other DCMs it is
defined by **left-ventricular (LV) dilation and systolic dysfunction** (reduced
ejection fraction) not explained by abnormal loading conditions or coronary
disease, presenting clinically as heart failure and predisposing to arrhythmia.
CMD2B is distinguished from the far more common autosomal-dominant DCMs by its
recessive transmission with clinically silent heterozygous carriers
[human clinical, PMID 21965549].

**Key identifiers.**
| Resource | ID |
|---|---|
| Mondo | **MONDO:0013848** (dilated cardiomyopathy 2B) |
| OMIM (phenotype) | **614672** — CARDIOMYOPATHY, DILATED, 2B; CMD2B |
| OMIM (gene) | **614518** — GATAD1 |
| HGNC | **HGNC:29941** (GATAD1) |
| NCBI Gene | **57798** |
| Ensembl | ENSG00000157014 |
| UniProt | Q8WUU5 (GATD1_HUMAN) |
| RefSeq | NM_021167.5 / NP_066990.3 (GATAD1, 249 aa); LRG_746 |
| Founder variant | NM_021167.5:c.304T>C (p.Ser102Pro); ClinVar VCV31656; rs387907188 |
| ICD-10 | I42.0 (Dilated cardiomyopathy) |
| ICD-11 | BC43.0 (Dilated cardiomyopathy) |
| MeSH | D002311 (Cardiomyopathy, Dilated) |
| Orphanet | within ORPHA:154 (Familial isolated dilated cardiomyopathy) — no distinct subtype code |

**Synonyms / alternative names.** CMD2B; Cardiomyopathy, dilated, 2B;
GATAD1-related/GATAD1-associated dilated cardiomyopathy; autosomal recessive
dilated cardiomyopathy (GATAD1 type).

**Data source type.** Disease-level aggregated resources (OMIM/Mondo) plus
**individual-patient** data from one published family; no EHR/registry-scale
cohort exists for this specific subtype.

---

## 2. Etiology

**Primary causal factor — genetic.** CMD2B is a **monogenic, biallelic** disorder.
Disease requires two loss-/alteration-of-function alleles of **GATAD1**. In the
index family a homozygous missense mutation altering the conserved **serine-102**
residue (reported as **p.Ser102Pro**) segregated with recessive DCM; it was
absent from HapMap, 1000 Genomes and 474 ethnically matched controls
[human clinical, PMID 21965549].

> "altered a conserved residue of GATAD1 … Thirteen relatives were heterozygous
> mutation carriers with no evidence of myocardial disease, even at advanced
> ages." (PMID 21965549)

**Genetic risk factors.**
- Causal variant: homozygous **GATAD1 p.Ser102Pro** (7q21.2). Because unaffected
  heterozygotes exist, a single allele is insufficient (recessive).
- **Consanguinity** is a major predisposing structural factor — the founding
  couple were first cousins, and homozygosity mapping exploited runs of
  homozygosity [human clinical, PMID 21965549].
- Modifier genes: none specifically identified for CMD2B (data unavailable).

**Environmental / lifestyle risk factors.** No CMD2B-specific environmental
trigger is established. For DCM broadly, alcohol, cardiotoxic chemotherapy
(anthracyclines), myocarditis/viral infection, peripartum state, thyroid disease
and tachyarrhythmia are recognized acquired causes/"second hits"; these may act
as **gene–environment modifiers** superimposed on genetic susceptibility
[DCM-class; PMID 42537484 notes "second-hit" genetic contributions]. Not
demonstrated for GATAD1 specifically.

**Protective factors.** No genetic or environmental protective factor is
described for CMD2B (data unavailable). By inference, absence of a second
pathogenic allele is "protective" (heterozygotes unaffected).

**Gene–environment interactions.** Mouse data suggest GATAD1 becomes functionally
important under **stress**: cardiac Gatad1 loss worsens ischemia–reperfusion
injury and abolishes sphingosylphosphorylcholine cardioprotection
[model organism, PMID 39626862], implying environmental/metabolic stressors may
unmask or aggravate GATAD1-deficient myocardium — inferred, not shown in patients.

---

## 3. Phenotypes

All descriptions derive from the single reported kindred [human clinical,
PMID 21965549] plus generic DCM knowledge.

| Phenotype | Type | HPO term | Onset / severity / course | Frequency |
|---|---|---|---|---|
| Dilated cardiomyopathy | clinical/imaging sign | **HP:0001644** | Adult-onset, progressive | Core, defining (homozygotes) |
| Left ventricular enlargement / dilatation | imaging sign | **HP:0001640** (cardiomegaly), HP:0001712 (LV hypertrophy—N/A) | Adult; may be isolated/milder | Present incl. an "intermediate" male |
| Reduced LV ejection fraction / systolic dysfunction | imaging/functional | **HP:0001635** (congestive heart failure), HP:0005162 (abnormal LV function) | Progressive | Core |
| Congestive heart failure (dyspnea, fatigue, edema) | symptoms | **HP:0001635** | Adult, progressive | Expected in overt cases |
| Arrhythmia / risk of sudden death | sign | **HP:0011675** (arrhythmia) | Variable | DCM-class risk; not detailed for CMD2B |
| Abnormal cardiomyocyte nuclear morphology | pathology (biopsy) | (cellular) | — | Seen in proband myocardium |

**Phenotype characteristics.** Age of onset: **adult-onset** (HP:0003581) with
**age-dependent penetrance**; the affected sisters were adults, and a brother had
milder "idiopathic LV enlargement," illustrating **variable expressivity**
(HP:0003828). Severity ranges from isolated LV dilatation to overt DCM/heart
failure. Course: **chronic, progressive**.

**Quality-of-life impact.** No CMD2B-specific QoL data. For symptomatic DCM/heart
failure generally, health-related QoL is substantially reduced (dyspnea,
exertional limitation, hospitalizations); disease-specific instruments include
the Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart
Failure Questionnaire (data unavailable for this subtype).

---

## 4. Genetic / Molecular Information

**Causal gene.** **GATAD1** — GATA zinc-finger domain-containing protein 1;
7q21.2; HGNC:29941; NCBI Gene 57798; OMIM 614518; UniProt Q8WUU5. Encodes a
nuclear protein containing a **GATA-type zinc finger** that functions as a
**reader of H3K4me3** and a subunit of a histone-modifying chromatin complex
[in vitro, PMID 26841866; 39641830].

**Pathogenic variant (founder allele of the index family).**
- **HGVS:** **GATAD1 NM_021167.5:c.304T>C**, protein **p.Ser102Pro**
  (LRG_746; UniProt Q8WUU5:p.Ser102Pro); genomic **chr7:g.92078120T>C (GRCh38)**
  [database-verified, ClinVar].
- **Identifiers:** **ClinVar Variation ID 31656**; **dbSNP rs387907188**.
- **Type/class:** single-nucleotide **missense**; **germline**; homozygous in
  affected individuals [human clinical, PMID 21965549].
- **Classification:** **Pathogenic** in ClinVar for "Dilated cardiomyopathy 2B"
  (review status: *no assertion criteria provided* — 1-star). Ser102 is
  N-terminal to the GATA-type zinc finger, within the intrinsically disordered
  region bearing the 14-3-3 phospho-motif. In-silico: **CADD 21.8**,
  **PolyPhen-2 probably damaging**; SIFT tolerated (mildly discordant).
- **Allele frequency:** **absent from gnomAD** (genomes and exomes) and absent
  from HapMap, 1000 Genomes and 474 matched controls [PMID 21965549] — private/
  ultra-rare.
- **Broader GATAD1 landscape:** most GATAD1 ClinVar entries are **VUS or likely
  benign**; only rare truncating variants are (likely) pathogenic. GATAD1 is
  frequently reported as **VUS** on cardiomyopathy panels (PMID 38664609,
  40200748) — caution for novel variants.
- **Functional consequence:** the mutation destroys a **phospho-serine 14-3-3
  docking site**, altering GATAD1 nucleocytoplasmic transport and producing
  aberrant subcellular localization and abnormal nuclear morphology
  [in vitro, PMID 38605029; human IHC, PMID 21965549]. Mechanistically this is
  **not a simple null** (see §6): a cardiomyocyte Gatad1 knockout mouse is
  healthy [PMID 39641830], suggesting an aberrant-function/mislocalization
  effect rather than pure loss-of-function.

**Modifier genes / epigenetic / chromosomal.** No CMD2B-specific modifier genes,
constitutional epigenetic marks, or chromosomal abnormalities reported (data
unavailable). Note GATAD1 itself acts within an **epigenetic (histone-modifying)**
complex — see §6.

---

## 5. Environmental Information

No environmental factor, occupational exposure, toxin, or infectious agent is
implicated in the causation of **CMD2B specifically** (it is a monogenic disease;
data unavailable). Generic DCM environmental contributors (alcohol, anthracyclines,
viral myocarditis, peripartum state) may act as aggravating **second hits** on a
genetically susceptible myocardium but are unproven for GATAD1. No infectious
agent applies.

---

## 6. Mechanism / Pathophysiology

### Ordered causal chain (initiating lesion → clinical manifestation)

1. **Homozygous GATAD1 p.Ser102Pro** substitutes proline for a serine
   phosphorylation site → **abolishes a phospho-Ser 14-3-3 docking motif**
   [in vitro, PMID 38605029].
2. Loss of 14-3-3 binding → **dysregulated masking of a nuclear localization
   signal** → **altered nucleocytoplasmic transport / mislocalization** of GATAD1
   [in vitro, PMID 38605029]; observed as **aberrant subcellular localization and
   abnormal nuclear morphology** in patient LV myocytes [human clinical, PMID 21965549].
3. Mislocalized/altered GATAD1 → **disrupted incorporation/function within the
   EMSY–KDM5A(H3K4me3 demethylase)–SIN3B/HDAC histone-modifying complex**
   [in vitro, PMID 26841866] → **altered H3K4me3-linked transcriptional
   regulation** at target promoters [inferred].
4. **Branch A (transcriptional/chromatin):** dysregulated cardiac gene expression
   programs → impaired maintenance of normal cardiomyocyte structure/function
   → **contractile dysfunction** [inferred from PMID 21965549, 26841866].
5. **Branch B (metabolic):** as a transcription factor GATAD1 normally represses
   fatty-acid-oxidation genes (**Acaa2**, **Acadm**) and promotes glucose
   oxidation; its dysfunction **shifts myocardial substrate metabolism and
   lowers stress tolerance** (larger infarcts / worse function under
   ischemia–reperfusion) [model organism, PMID 39626862].
6. Converging branches → **cardiomyocyte dysfunction** → **LV chamber dilation
   and systolic dysfunction (reduced EF)** [human clinical, PMID 21965549].
7. → **congestive heart failure**, and (DCM-class) predisposition to **ventricular
   arrhythmia / sudden cardiac death** → end-stage disease potentially requiring
   transplantation.

> Steps 1–2 are experimentally demonstrated; step 3 (complex membership) is
> demonstrated biochemically but not in heart tissue; steps 4–7 are **inferred**
> from correlative human pathology and model-organism data. A key unresolved
> point: cardiomyocyte-specific Gatad1 **deletion does not cause disease in mouse**
> (PMID 39641830), so the pathogenic mechanism likely involves an **aberrant/
> dominant-negative-like** effect of the mislocalized mutant and/or non-cell-
> autonomous or developmental requirements — not simple loss-of-function.

### Detail by category
- **Molecular pathways:** chromatin/epigenetic regulation via H3K4me3
  reading/demethylation (KDM5A) and Sin3/HDAC deacetylation; 14-3-3 signaling.
  GO: **GO:0006325** (chromatin organization), **GO:0034968** (histone lysine
  methylation), **GO:0032452** (histone demethylase activity), **GO:0000122**
  (negative regulation of transcription).
- **Cellular processes:** transcriptional regulation, nucleocytoplasmic transport
  (**GO:0006913**), cardiac muscle contraction; metabolic gene regulation.
- **Protein dysfunction:** loss of a regulatory phosphosite → altered
  protein–protein interaction (14-3-3) and mislocalization; GATAD1 is intrinsically
  disordered in the relevant region [in vitro, PMID 38605029].
- **Metabolic changes:** dysregulated balance of **fatty-acid oxidation
  (GO:0019395)** vs **glucose oxidation** [model organism, PMID 39626862].
- **Immune involvement:** none established (non-inflammatory genetic cardiomyopathy).
- **Tissue-damage mechanisms:** DCM-class remodeling — cardiomyocyte dysfunction,
  interstitial/replacement fibrosis, chamber dilation; increased ischemic
  vulnerability [inferred/model].
- **Epigenetic changes:** GATAD1 is itself part of the epigenetic machinery
  (H3K4me3 reader). Disease-associated global methylation changes: data unavailable.
- **Cell types:** cardiac muscle cell / cardiomyocyte — **CL:0000746**
  (ventricular cardiomyocyte **CL:0002131**).

---

## 7. Anatomical Structures Affected

- **Organ (primary):** heart — **UBERON:0000948**; specifically **left ventricular
  myocardium / heart left ventricle — UBERON:0002084** (myocardium UBERON:0002349).
- **Secondary/systemic:** cardiovascular system (UBERON:0004535); congestive heart
  failure secondarily affects lungs (pulmonary congestion), kidneys, liver
  (congestion). Body system: **cardiovascular**.
- **Tissue/cell:** striated **cardiac muscle** tissue; **cardiomyocytes (CL:0000746 /
  ventricular CL:0002131)** are the primary affected cell population.
- **Subcellular:** **nucleus (GO:0005634)** — GATAD1 is nuclear; the defect centers
  on nuclear import/nuclear morphology. Chromatin (**GO:0000785**). A metabolic
  arm implicates **mitochondrial** fatty-acid oxidation machinery indirectly
  (GO:0005739) [inferred].
- **Localization / laterality:** predominantly **left ventricular**; DCM is
  typically **global/bilateral** ventricular involvement rather than focal.

---

## 8. Temporal Development

- **Onset:** **adult-onset** (HP:0003581), **insidious/chronic**; **age-dependent
  penetrance** (an explicit rationale for building an adult zebrafish model,
  PMID 28955713). No neonatal/pediatric CMD2B cases reported.
- **Progression:** chronic and **progressive**; ranges from isolated LV
  enlargement (intermediate phenotype) to overt DCM with systolic dysfunction and
  heart failure [human clinical, PMID 21965549]. DCM-class staging: early
  (asymptomatic LV dilation) → symptomatic HF → advanced/end-stage.
- **Course pattern:** progressive, lifelong (chronic). No spontaneous remission
  documented for CMD2B; DCM broadly can show reverse remodeling with
  guideline-directed therapy.
- **Critical periods:** adulthood is the window of clinical expression; the
  pre-symptomatic phase is the opportunity for surveillance/early therapy in
  at-risk homozygotes.

---

## 9. Inheritance and Population

- **Inheritance:** **autosomal recessive** (a defining, unusual feature — most DCM
  is autosomal dominant). Heterozygous carriers are unaffected even at advanced
  age [human clinical, PMID 21965549].
- **Penetrance:** appears high in homozygotes but **age-dependent**; **carriers
  non-penetrant**.
- **Expressivity:** **variable** (isolated LV enlargement → overt DCM within one
  family).
- **Consanguinity:** central — index family descended from first cousins;
  homozygosity mapping was the discovery strategy [PMID 21965549].
- **Founder effect / geographic variant distribution / anticipation / germline
  mosaicism:** none reported (data unavailable). No repeat expansion (no
  anticipation expected).
- **Carrier frequency:** not established; the specific allele is private/ultra-rare
  (absent from population databases).
- **Epidemiology:** No prevalence/incidence figures exist for CMD2B specifically —
  it is **exceedingly rare** (essentially one published kindred). For context,
  **DCM overall** has an estimated prevalence on the order of **~1 in 250–500**
  and a monogenic cause is identifiable in **~30–40%** of familial cases
  (PMID 39855353); GATAD1 accounts for only a tiny fraction. Sex ratio: DCM
  overall is male-predominant; both sexes affected in the CMD2B family (the two
  fully affected probands were female). Age distribution: adults.

---

## 10. Diagnostics

**Cardiac phenotyping (DCM-class, applied to CMD2B).**
- **Imaging:** transthoracic **echocardiography** (LV dilation, reduced LVEF) —
  first-line; **cardiac MRI** (chamber volumes, function, late-gadolinium
  fibrosis) [DCM-class; stress echo relevance PMID 18579481]. LOINC/RadLex apply.
- **ECG / Holter:** arrhythmia and conduction assessment.
- **Biomarkers:** **NT-proBNP/BNP** (heart-failure severity); troponin as adjunct
  (non-specific). No CMD2B-specific circulating biomarker.
- **Endomyocardial biopsy:** not routine; in the proband it revealed **aberrant
  cardiomyocyte nuclear morphology / GATAD1 mislocalization** [PMID 21965549].

**Genetic testing (definitive for subtype).**
- Recommended approach: **NGS cardiomyopathy multigene panel** (GATAD1 is included
  on modern panels, PMID 38664609) or **whole-exome/genome sequencing**; the
  original diagnosis used **homozygosity mapping + exome sequencing** in a
  consanguineous pedigree [PMID 21965549].
- Confirm **biallelic** GATAD1 variants (homozygous or compound heterozygous) with
  segregation; classify per ACMG/AMP (many GATAD1 variants are currently VUS).
- CMA/karyotype/FISH/mtDNA/repeat-expansion testing: **not indicated** for this
  single-gene point-mutation disorder.

**Clinical criteria / differential diagnosis.** Diagnose DCM by LV dilation +
systolic dysfunction after excluding ischemic, valvular, hypertensive, toxic
(alcohol/anthracycline), infiltrative, peripartum and myocarditic causes.
Differential: other genetic DCMs (TTN, LMNA, RBM20, FLNC, DES, MYH7), arrhythmogenic
and hypertrophic cardiomyopathies. The recessive pattern + consanguinity + GATAD1
genotype distinguishes CMD2B.

**Screening.** **Cascade genetic testing** of relatives and **echocardiographic
surveillance** of at-risk biallelic individuals (see §13). Family screening yields
~10% at baseline and ~10% more over 5 years in DCM generally (PMID 39833651).

---

## 11. Outcome / Prognosis

- **CMD2B-specific outcome data are essentially absent** beyond the index family
  (adult-onset DCM/heart failure). No survival, mortality or QoL statistics exist
  for this subtype.
- **By DCM class:** prognosis depends on LVEF and remodeling. In a large registry,
  patients presenting with **mid-range EF (40–49%)** had markedly better outcomes
  than reduced-EF (<40%) patients — death/transplant **9% vs 36%** and SCD/major
  ventricular arrhythmia **4.5% vs 15%** over ~10 years (PMID 31431100); ~17% of
  mid-range progressed to reduced EF.
- **Complications:** progressive heart failure, ventricular arrhythmia/**sudden
  cardiac death**, atrial fibrillation, thromboembolism, and end-stage disease
  requiring **heart transplantation** (genetic DCMs are enriched among transplant
  recipients, PMID 42537484).
- **Recovery:** reverse remodeling possible with guideline-directed therapy in
  DCM broadly; not documented specifically for CMD2B.
- **Prognostic factors:** LVEF, LV size, fibrosis on MRI, arrhythmia burden,
  NT-proBNP (DCM-class). No validated CMD2B-specific prognostic biomarker.

---

## 12. Treatment

**No gene-specific or curative therapy exists for CMD2B.** Management follows
**guideline-directed medical therapy (GDMT) for DCM/heart failure with reduced
ejection fraction**:

- **Pharmacotherapy (NCIT terms in brackets):**
  - **ACE inhibitors / ARBs / ARNI** (sacubitril–valsartan) — afterload/neurohormonal.
  - **Beta-blockers** (carvedilol, metoprolol succinate, bisoprolol).
  - **Mineralocorticoid-receptor antagonists** (spironolactone, eplerenone).
  - **SGLT2 inhibitors** (dapagliflozin, empagliflozin).
  - **Diuretics** for congestion; anticoagulation if AF/thrombus.
  - NCIT: *ACE Inhibitor*, *Beta-Adrenergic Blocker*, *Diuretic*, *Aldosterone
    Antagonist*.
- **Pharmacogenomics:** no GATAD1-specific PGx. General HF PGx (e.g., warfarin
  CYP2C9/VKORC1) applies only if those drugs are used.
- **Device / interventional:** **ICD** for sudden-death prevention and **CRT** for
  conduction delay per EF/QRS criteria; mitral intervention as indicated.
- **Advanced / surgical:** **mechanical circulatory support (LVAD)** and **heart
  transplantation** for end-stage disease.
- **Advanced therapeutics (gene/cell/RNA/targeted/immunotherapy):** **none
  approved or in trials for GATAD1-DCM** (data unavailable). Gene-directed
  strategies are conceptual only.
- **Supportive/rehabilitative:** cardiac rehabilitation, sodium/fluid guidance,
  exercise counseling, HF self-management.
- **Experimental / trials:** no CMD2B-specific registered trials identified.
- **Personalized approach:** genotype confirmation guides **family screening and
  reproductive counseling** rather than drug selection at present.

---

## 13. Prevention

- **Primary prevention:** not possible for the genetic cause; **preconception/
  reproductive genetic counseling** in consanguineous or carrier families is the
  main lever. Options: carrier testing of partners, **prenatal diagnosis** or
  **preimplantation genetic testing (PGT-M)** for known biallelic risk.
- **Secondary prevention:** **cascade genetic testing** of relatives and
  **serial echocardiographic surveillance** of biallelic (homozygous/compound-het)
  at-risk individuals to detect subclinical LV dysfunction early; genotype-guided
  screening is efficient because non-carriers of the familial variant do not
  develop disease (PMID 39833651). ACMG/HFSA recommend genetic evaluation +
  family screening in familial DCM.
- **Tertiary prevention:** GDMT, ICD for arrhythmic death, HF-hospitalization
  avoidance, management of AF/thromboembolism.
- **Behavioral:** avoid alcohol excess and cardiotoxins; standard cardiovascular
  risk-factor control (may mitigate "second-hit" aggravation — inferred).
- **Counseling:** autosomal-recessive counseling — **25% recurrence** risk for
  future sibs of an affected child; offspring of an affected person are obligate
  carriers (affected only if partner is also a carrier). Immunization/public-health
  and environmental interventions: not applicable.

---

## 14. Other Species / Natural Disease

- **Taxonomy / orthologs:** GATAD1 is evolutionarily conserved.
  - Human **GATAD1** — NCBI Gene **57798**, HGNC:29941, 7q21.2 (*Homo sapiens*, Taxon **9606**).
  - Mouse *Gatad1* — **NCBI Gene 67210** (*Mus musculus*, NCBI Taxon **10090**; chr5 A1).
  - Zebrafish *gatad1* — **NCBI Gene 678617** (*Danio rerio*, NCBI Taxon **7955**).
- **Natural disease in other species:** No naturally occurring GATAD1
  cardiomyopathy in companion animals or wildlife is catalogued (no OMIA entry
  identified; data unavailable). Note: naturally occurring **DCM** is common in
  dogs (e.g., Doberman Pinscher, Great Dane) but is genetically distinct
  (not GATAD1).
- **Comparative biology / conservation:** the H3K4me3-reader/chromatin-complex
  function and the Ser102/14-3-3 regulatory motif are conserved, enabling
  cross-species modeling; however, **phenotypic conservation is incomplete** —
  zebrafish reproduce DCM whereas mouse cardiomyocyte knockout does not (§15).
- **Transmission / zoonosis:** not applicable (non-communicable genetic disease).

---

## 15. Model Organisms

**Zebrafish (Danio rerio, Taxon 7955) — supportive positive model.**
Yang, Shah, Olson & Xu 2016 (PMID 28955713) generated an **adult zebrafish** model
of the *gatad1* homologue specifically to overcome age-dependent penetrance and
validate GATAD1 as a bona fide DCM gene in a higher-throughput vertebrate.
> "we generated an adult zebrafish model, which is a simpler vertebrate model
> with higher throughput than rodents." (PMID 28955713)
- Model type: genetic vertebrate; application: validating causality, studying
  adult-onset cardiomyopathy mechanisms.

**Mouse (Mus musculus, Taxon 10090) — informative negative / limitation.**
Pang et al. 2024 (PMID 39641830) made a **cardiomyocyte-specific Gatad1 knockout
(cKO)**. It showed **normal cardiac function to 18 months**, **normal nuclear
shape** (unlike patients), and **normal response to pressure overload (TAC)**.
> "deletion of Gatad1 in cardiomyocytes does not induce cardiomyopathy during
> aging or affect the response to pressure-overload stress in mice." (PMID 39641830)
- Interpretation/limitation: pure cardiomyocyte loss-of-function is insufficient in
  mouse → argues the human p.Ser102Pro acts via aberrant function/mislocalization
  or non-cardiomyocyte/developmental requirements; a **knock-in of the p.Ser102Pro
  allele** would be the more faithful (still-needed) model.

**Additional mouse model (metabolic).** A myocardium-specific *Gatad1* cKO was used
to show GATAD1 controls the fatty-acid/glucose oxidation balance and modulates
ischemia–reperfusion injury (PMID 39626862).

**In vitro / cellular systems.** Peptide-interaction proteomics and structural
studies of the Ser102 phosphosite–14-3-3 interaction (PMID 38605029); biochemical
characterization of the EMSY/KDM5A/SIN3B complex (PMID 26841866). No iPSC-
cardiomyocyte CMD2B model is yet reported (opportunity/gap).

**Resources:** MGI (mouse *Gatad1*), ZFIN (zebrafish *gatad1*), Alliance of Genome
Resources.

---

## Summary of Supported vs. Refuted / Open Hypotheses

- **Supported:** CMD2B = autosomal-recessive DCM caused by biallelic GATAD1
  (p.Ser102Pro); GATAD1 is a nuclear H3K4me3-reader/chromatin-complex subunit; the
  mutation disrupts a Ser102 phospho-14-3-3 motif and GATAD1 nuclear localization;
  GATAD1 regulates cardiac substrate metabolism; zebrafish recapitulate DCM.
- **Refuted / qualified:** "simple cardiomyocyte loss-of-function causes the
  disease" — **refuted** in mouse cKO (PMID 39641830); mechanism is more likely
  aberrant-function/mislocalization.
- **Resolved this review:** founder allele nomenclature and status —
  GATAD1 NM_021167.5:c.304T>C (p.Ser102Pro), ClinVar VCV31656/rs387907188,
  **Pathogenic**, **absent from gnomAD**.
- **Open / data-unavailable:** population carrier frequency; CMD2B-specific
  penetrance %, survival, QoL; modifier genes; existence of additional families
  beyond the index kindred; iPSC and knock-in (p.Ser102Pro) models.

## Limitations
Human evidence rests on one consanguineous kindred; mechanism is pieced together
from in-vitro and cross-species models with a notable mouse/zebrafish discordance.
Epidemiologic, prognostic, and treatment-response data specific to CMD2B do not
exist and were substituted with clearly-labeled DCM-class information.

## Key References (PMIDs)
- 21965549 — Theis et al. 2011: discovery of GATAD1 in AR-DCM [human clinical].
- 38605029 — Rrustemi et al. 2024: Ser102/14-3-3, nucleocytoplasmic transport [in vitro].
- 26841866 — Varier et al. 2016: EMSY/KDM5A/SIN3B complex, GATAD1 subunit [in vitro].
- 28955713 — Yang et al. 2016: adult zebrafish gatad1 DCM model [model organism].
- 39641830 — Pang et al. 2024: cardiomyocyte Gatad1 cKO — no cardiomyopathy [model organism].
- 39626862 — Cai et al. 2025: GATAD1 controls FAO/glucose oxidation, I/R injury [model organism].
- 38664609 / 40200748 / 39833651 / 39855353 — DCM genetic testing & family screening context.
- 31431100 — DCM natural history by EF stratum [human clinical, DCM-class].


## Artifacts

- [OpenScientist final report](Dilated_Cardiomyopathy_2B-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Dilated_Cardiomyopathy_2B-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0rc1.

| Outcome | Count |
| --- | --- |
| References checked | 12 |
| Resolved | 12 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 12 |
| On topic | 7 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 26 |
| Resolved | 23 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 1 |
| Unverifiable | 2 |
| Terms whose name was checked | 5 |
| Terms named correctly | 1 |
| Terms named as a **different** term | 2 |
| Terms whose name is worth a second look | 2 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0001644` (1 mention) - the report calls it "clinical/imaging sign"; HP calls it **Dilated cardiomyopathy**
- `HP:0001635` (2 mentions) - the report calls it "symptoms"; HP calls it **Congestive heart failure**

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `GO:0034968` (obsolete histone lysine methylation) (1 mention)

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `UBERON:0004535` (1 mention) - the report calls it "Secondary/systemic:** cardiovascular system"; UBERON calls it **cardiovascular system**
- `GO:0005634` (1 mention) - the report calls it "Subcellular:** **nucleus"; GO calls it **nucleus**, and lists "cell nucleus" among its other names

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `HP:0003581` - called "adult-onset", "Onset:** **adult-onset"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.